Clinical trials: Epithelial Neoplasms, Malignant
Glioma
Use of Pulsed Low-dose Rate Re-irradiation for Recurrent Glioma (PULSAR)
Re-irradiation in gliomas is a therapeutic option at recurrence before of 2nd-line chemotherapy. The dose of re-irradiation with conventional fractionation is unfortunately limited by the risk of symptomatic radionecrosis that is…
- Trial name
- PULSAR (NCT06055517)
- Testing
- Pulsed low dose-rate radiotherapy (pLDRT)
- Where
- Italy
- Volunteers
- 29 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Metastatic Clear Cell Renal Cell Carcinoma
Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma
The purpose of this study is to validate of a predictive nomogram of response or resistance to targeted therapies in metastatic clear cell renal cell carcinoma
- Trial name
- RTKI (NCT02848768)
- Testing
- Sunitinib
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Rennes University Hospital
Metastatic Renal Cell Carcinoma, Metastatic Malignant Melanoma
Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose of AS1409 in single and repeated doses.
- Trial name
- NCT00625768
- Testing
- AS1409
- Where
- 4 sites in New Zealand, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Antisoma Research
Insulinoma
Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma
Glucagon-like peptide-1 receptor (GLP-1R) is a kind of G protein coupled receptor which regulate the insulin secretion and serves as potential target in the diagnosis of functional pancreas neuroendocrine tumor.
- Trial name
- NCT04185350
- Testing
- 68Ga-NOTA-MAL-Cys39-exendin-4
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Melanoma (Skin), Neuroblastoma
Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors
RATIONALE: Biological therapies such as hu14.18-interleukin-2 fusion protein use different ways to stimulate the immune system and stop cancer cells from growing.
- Conditions
- Melanoma (Skin), Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00003750
- Testing
- hu14.18-IL2 fusion protein
- Where
- 59 sites in United States, Australia and 1 more
- Volunteers
- 28 people
- Sponsor
- Children's Oncology Group
Peritoneal Diseases
ERAS® Guidelines Validation of CRS With or Without HIPEC
Enhanced recovery after surgery (ERAS®) pathways have been shown to considerably reduce complications, length of stay and costs after most of surgical procedures by standardised application of best evidence-based perioperative…
- Trial name
- NCT05185791
- Testing
- Pre-ERAS® phase (current clinical practice), Post-ERAS® implementation phase
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 288 people
- Sponsor
- Hospices Civils de Lyon
Hepatocellular Carcinoma
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- TAQE (NCT05842174)
- Testing
- Hydroxychloroquine, Lipiodol
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- VA Office of Research and Development
Ductal Breast Carcinoma in Situ, Invasive Breast Cancer
Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.
An explanatory study comparing complementary treatment to breast conservative surgery with radiation therapy DCIS, T1-T2 N0 M0 (AJCC v8) 1 week schedule vs 3.1 weeks standard schedule, in order to determine the equivalence of…
- Conditions
- Ductal Breast Carcinoma in Situ, Invasive Breast Cancer, Early-stage Breast Cancer, Stage 0 Breast Cancer
- Trial name
- NCT05318274
- Testing
- Hypofractionated radiotherapy
- Where
- Mexico
- Volunteers
- 72 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Squamous Cell Carcinoma
Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma
Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor (EGFR). Clinical trials are ongoing globally to evaluate Nimotuzumab in different indications.
- Trial name
- NCT01232374
- Testing
- Nimotuzumab, cisplatin, Radiotherapy
- Where
- 17 sites in China
- Volunteers
- 144 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Cervical Cancer
Cervical Carcinoma in Shatby University Hospital and Its Relation to Human Papilloma Virus
incidence of detection of carcinogenic types of human papilloma virus in 60 cases of cervical cancer
- Trial name
- NCT05539274
- Testing
- human papilloma virus testing and genotyping in cervical cancer cases
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Hossam Hassan Aly Hassan El Sokkary
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)
This study will evaluate the safety of BXQ-350 and determine the maximum tolerated dose (MTD) in children with newly diagnosed DIPG or DMG. All patients will receive BXQ-350 by intravenous (IV) infusion and radiation therapy.
- Trial name
- KONQUER (NCT04771897)
- Testing
- BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance, BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bexion Pharmaceuticals, Inc.
Bladder Urothelial Carcinoma, Bladder Cancer
Safety Analysis and Oncological Outcomes in HoLERT vs TURBT
Bladder urothelial cancer is the second most common urologic tumor and represents a worldwide public health problem. Most cases are diagnosed as non-muscle invasive tumors, and can be treated with transurethral resection of…
- Trial name
- NCT05833997
- Testing
- Monopolar Transurethral resection of bladder tumor, Holmium Laser resection of bladder tumor (HoLEBT)
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Bladder Cancer
Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy
The goal of this clinical research study is to learn about the tolerability of nivolumab in patients who have bladder cancer, were previously treated with BCG immunotherapy, and who have a cystectomy (removal of all or part of…
- Trial name
- NCT03106610
- Testing
- Nivolumab, Questionnaires
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
HPV InfectioN, HPV-Related Carcinoma
A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-45 Years
A total of 13500 Chinese women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 35-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1.
- Trial name
- NCT05262010
- Testing
- 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
- Where
- 8 sites in China
- Volunteers
- 13,500 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Non-small Cell Lung Cancer
Prediction of Mediastinal Station IV Lymph Node Metastasis in Non-small Cell Lung Cancer
Mediastinal lymph node metastasis is a common metastasis pathway of non-small cell lung cancer (NSCLC), and its occurrence is closely related to the lymphatic drainage pattern, which is different in different pulmonary lobe…
- Trial name
- NCT06496360
- Testing
- Artificial Intelligence
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Qilu Hospital of Shandong University
Thyroid Carcinoma
Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
This is a non-interventional, multi center post-authorization safety study that includes all patients diagnosed as Unresectable Differentiated Thyroid Carcinoma (DTC) and treated with Sorafenib within a certain period.
- Trial name
- JPMS-DTC (NCT02185560)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Japan
- Volunteers
- 453 people
- Sponsor
- Bayer
Lung Cancer, Nonsmall Cell, COPD
Breathe Easier II: A Dyad-based Multiple Behavior Intervention
This pilot randomized control trial (RCT) will test a 12-week, multiple behavior intervention physical activity and stress management for survivors with early stage lung cancer (stages I-III) and their family members (1 survivor…
- Conditions
- Lung Cancer, Nonsmall Cell, COPD, Self-Management, Physical Inactivity
- Trial name
- BE (NCT05956782)
- Testing
- Breathe Easier
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of South Carolina
Fallopian Tube Carcinoma, Ovarian Carcinoma
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
This phase II trial studies how well giving the insulin-like growth factor binding protein 2 [pUMVC3-hIGFBP-2 multi-epitope plasmid deoxyribonucleic acid (DNA) (IGFBP-2)] vaccine after one dose of carboplatin works to stop…
- Conditions
- Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT07495124
- Testing
- pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, Carboplatin, Computed Tomography
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Washington
Glioblastoma, Glioblastoma Multiforme (GBM)
The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in…
- Trial name
- GUAVA (NCT07052877)
- Testing
- PSMA PET/CT scan
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Royal North Shore Hospital
Non-small Cell Lung Cancer, Minimal Residual Disease
Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation
To study the efficacy of sintilimab combined with anlotinib for perioperative non-small cell lung cancer. To explore the clearance effect of sintilimab combined with anlotinib for postoperative adjuvant therapy based on…
- Conditions
- Non-small Cell Lung Cancer, Minimal Residual Disease, Immunotherapy, Anti-angiogenesis
- Trial name
- NCT05460195
- Testing
- sintilimab combined with anlotinib, sintilimab monotherapy
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Shanghai Chest Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.